Business Wire

Hyperice Introduces Hypervolt Go 2 as Everyday Wellness Essential for All

4.4.2022 13:00:00 EEST | Business Wire | Press release

Share

Hyperice, a global high-performance wellness brand, today introduced a new and improved version of its original, award-winning handheld massage gun, the Hypervolt Go. Leveling up and standing on its own within the percussive massage category, the newly redesigned, lightweight and versatile Hypervolt Go 2 is the most sophisticated portable percussion massager to hit the wellness market and is built to increase people’s range of motion with just a five minute treatment each day1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005376/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hyperice Introduces Hypervolt Go 2 as Everyday Wellness Essential for All (Photo: Business Wire)

The Hypervolt Go 2 adds to the company’s range of powerful percussion devices including the recently launched Hypervolt 2 and Hypervolt 2 Pro, all of which help everyday users and pro athletes alike massage away stress and muscle tension from the palm of their hand.

“For over 10 years, Hyperice has been relentlessly focused on developing innovative products to help people across the globe move and live better. The new Hypervolt Go 2 offers a unique combination of performance and portability for the wellness-minded consumer,” said Jim Huether, CEO of Hyperice. “Designed for the everyday go-getter, the Hypervolt Go 2 is a wellness essential - perfect for everyone who is moving at home or on the road and wants to be at their best everyday.”

“The Hypervolt Go 2 is the result of our 'design first’ approach to creating a product that looks as good as it feels. We wanted to design a product that people would want to take and use everywhere they go,” said Anthony Katz, Founder and President of Hyperice. “With this newest addition to the Hypervolt family, the Hypervolt Go 2 offers more choice, to more people, in more places than ever before.”

WELLNESS THAT MOVES WITH YOU

The new Hypervolt Go 2 has a sophisticated design that features minimalistic looks with an arctic-grey finish and feels great in your hand and on your body. It is built to last, with high-quality materials and intuitive ergonomics. The Hypervolt Go 2 is designed to move conveniently wherever users are headed and includes features such as:

  • Patented QuietGlide® technology for near silent operation
  • Improved airflow and ventilation
  • New LED speed sensors and back button control
  • New ergonomic handle
  • Battery level LED band
  • Three speeds of powerful percussion

Go behind the design of the Hypervolt Go 2.

Katz continued: “Our mission from the beginning, was to put a percussion device in as many hands as possible. To do that, we need to continue to design products that are accessible to the widest possible audience of users. We also know, with the world opening back up, people are constantly on the move, and space can oftentimes be limited, so the smaller you can make the device, the more places you can take it, the more you can use it. Hypervolt Go 2 represents the next step towards achieving that goal.”

“My current phase of my career is about longevity and maintaining a competitive advantage,” said Kelly Slater, 11-time World Surf League champion and Hyperice Athlete-Investor. “To be my best when I’m competing, I have to also feel great no matter where I am, which is why I never leave home without the Hypervolt Go 2. It’s the ultimate in portability, it’s dead silent and it comes in clutch whether I’m preparing for a major event or just managing everyday aches.”

The Hypervolt Go 2 retails for $199 (£199; €229) and is now available in North America and other select regions. For more information, visit hyperice.com. To purchase, please visit country-specific sites: Canada, France, Germany, Italy, Portugal, Spain, UK and the United States.

To learn more about the Hypervolt Go 2, visit hyperice.com.

INTRODUCING: THE GO COLLECTIVE

To amplify the ethos of the Go line, Hyperice has assembled a diverse collection of individuals within #TeamHyperice who represent different industries and backgrounds who are pushing the boundaries of what it means to ‘go get it.’ The Go Collective seeks to make a movement out of movement across the many dimensions of fitness, fashion, lifestyle, sports, travel, longevity, wellness, art, family, and more. Through expansive storytelling and involvement in community initiatives and events, Hyperice hopes the Go Collective will inspire individuals everywhere to prioritize their daily wellness.

Meet the inaugural Go Collective members:

  • Robin Arzón, Head Instructor and VP of Fitness Programming at Peloton
  • Tony Finau, PGA TOUR Golfer
  • Adrianne Ho, Model and Founder of Sweat The Style & The Farmers Market Global
  • Joe Holder, Nike Master Trainer and Founder of The Ocho System™
  • Alix Klineman, Beach Volleyball Olympic Gold Medalist
  • Kelly Slater, Professional Surfer
  • Nigel Sylvester, Pro BMX Athlete and Content Creator
  • Raven B. Varona (Ravie B), Professional Photographer

“I’m proud to be a member of Hyperice’s new Go Collective because it represents a community for people who show up everyday for themselves and for others,” said Robin Arzón, Head Instructor and VP of Fitness Programming at Peloton. “I believe there is transformative power in movement and as a mom, wife and athlete, being able to be at my best in all dimensions of my life is what motivates me to ‘go get it’. Hyperice’s suite of products, and the Hypervolt Go 2 in particular, are my go-to wellness tools that help me be at my best each and every day.”

“I take my role as a husband and father of five even more seriously than my career as a pro golfer. There’s no doubt staying healthy is a huge part of my commitment to performance, but more importantly, it’s critical to me that I’m the best version of myself whenever I’m spending valuable time with my family,” said Tony Finau, PGA TOUR player and Hyperice investor. “The Hypervolt Go 2 goes with me everywhere – on the course during competition, training and recovery, and when I’m traveling between tournaments – to ensure that I can push to the limits of my full potential for years to come.”

“When it comes to feeling your best, a major part of that is making sure to move and to move effectively everyday, and recovery is a critical component of a holistic approach to an individual’s overall wellness,” said Joe Holder, Nike Master Trainer and Founder of The Ocho System™. “As someone who gets the opportunity to help so many people unlock their personal version of wellness, the Hypervolt Go 2 is an incredible tool for anyone to utilize to help ensure they can come back day after day - ready to be anything but average.”

To join the Go Collective community, follow Hyperice on social - instagram.com/hyperice and twitter.com/hyperice and sign up for emails on hyperice.com to unlock exclusive content, special offers, access to events and more. Learn more at: hyperice.com/newsroom/go-collective

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.

1 Journal of Sports Science & Medicine 2020

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jack Taylor PR
Nadine Hachicho
hyperice@jacktaylorpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye